US equities
|
NVDA
$239.87
▲+0.41%
SPCX
$173.31
▲+1.30%
MU
$1,064.78
▲+0.08%
MRVL
$286.90
▲+5.77%
AMD
$655.04
▲+3.69%
INTC
$114.26
▼-1.66%
AVGO
$379.77
▲+4.76%
SNDK
$1,673.80
▼-1.78%
NVDA
$239.87
▲+0.41%
SPCX
$173.31
▲+1.30%
MU
$1,064.78
▲+0.08%
MRVL
$286.90
▲+5.77%
AMD
$655.04
▲+3.69%
INTC
$114.26
▼-1.66%
AVGO
$379.77
▲+4.76%
SNDK
$1,673.80
▼-1.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Amgen
(NQ:
AMGN
)
400.81
-2.17 (-0.54%)
Delayed Quote
Updated: 1:36 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
3
4
5
6
7
8
9
...
72
73
Next >
2 Nasdaq 100 Stocks with Competitive Advantages and 1 We Question
May 04, 2026
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Via
StockStory
These S&P500 stocks are moving in today's session
↗
May 01, 2026
Via
Chartmill
Why the S&P 500 and Nasdaq Hit Record Highs While the Dow Fell Today
↗
May 01, 2026
Same market, different outcomes. Here's why Apple sent two indexes to record highs while the Dow slipped.
Via
The Motley Fool
Topics
Government
Stocks
World Trade
What's going on in today's session: S&P500 movers
↗
May 01, 2026
Via
Chartmill
Amgen Inc (NASDAQ:AMGN) Q1 Earnings Beat on EPS but Revenue Miss Sends Shares Lower
↗
April 30, 2026
Via
Chartmill
Topics
Earnings
Friday's session: gap up and gap down stock in the S&P500 index
↗
May 01, 2026
Via
Chartmill
What's going on in today's pre-market session: S&P500 movers
↗
May 01, 2026
Via
Chartmill
AMGN Q1 Deep Dive: Growth Drivers Offset Patent Losses, Pipeline Progress in Focus
May 01, 2026
Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2026, with sales up 5.8% year on year to $8.62 billion. The company expect...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Amgen (AMGN) Q1 2026 Earnings Transcript
↗
April 30, 2026
Amgen (AMGN) Q1 2026 Earnings Transcript
Via
The Motley Fool
Amgen’s (NASDAQ:AMGN) Q1 CY2026 Sales Top Estimates
April 30, 2026
Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 5.8% year on year to $8.62 billion....
Via
StockStory
Topics
Intellectual Property
EDMP picks up Sonoco, and the position size is doing the talking
↗
April 29, 2026
Sonoco Products Company delivers packaging solutions to global consumer and industrial markets, with a reported dividend yield of 4.2%.
Via
The Motley Fool
Topics
Regulatory Compliance
Earnings To Watch: Amgen (AMGN) Reports Q1 Results Tomorrow
April 28, 2026
Biotech company Amgen (NASDAQ:AMGN) will be announcing earnings results this Thursday afternoon. Here’s what investors should know. Amgen beat analysts’ reve...
Via
StockStory
2 Profitable Stocks with Competitive Advantages and 1 Facing Headwinds
April 27, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
3 Catalysts That Could Send Teva Stock to $40 and Beyond
↗
April 18, 2026
This once-beaten-down pharma stock remains an intriguing turnaround story.
Via
The Motley Fool
2 S&P 500 Stocks Worth Your Attention and 1 We Ignore
April 17, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Via
StockStory
Topics
Stocks
2 Dow Jones Stocks with Exciting Potential and 1 Facing Headwinds
April 16, 2026
While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising c...
Via
StockStory
Topics
Stocks
2 Reasons to Like AMGN and 1 to Stay Skeptical
April 15, 2026
Amgen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.8%. The stock now trades at $350.73, marking a 18% gain....
Via
StockStory
Topics
Stocks
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
April 14, 2026
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of...
Via
MarketMinute
Topics
Bankruptcy
Earnings
Economy
Johnson & Johnson Shatters Expectations in Q1 2026, Raising Full-Year Outlook as Healthcare Giant Pushes Toward $100 Billion Milestone
April 14, 2026
NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across...
Via
MarketMinute
Topics
Economy
Intellectual Property
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
April 14, 2026
As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc....
Via
Finterra
Topics
Economy
Initial Public Offering
Intellectual Property
Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
April 13, 2026
THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its...
Via
MarketMinute
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
April 13, 2026
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
Amgen Reclaims the Lead in Thyroid Eye Disease with Superior Subcutaneous TEPEZZA Data
April 09, 2026
In a major victory for its rare disease portfolio, Amgen (NASDAQ: AMGN) announced positive topline results on April 6, 2026, from its pivotal Phase 3 clinical trial evaluating a subcutaneous (SC)...
Via
MarketMinute
Topics
Intellectual Property
The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
April 08, 2026
In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the...
Via
MarketMinute
Martin Capital Dumps $4.5 Million in Robert Half Shares After a Brutal Year for the Staffing Sector
↗
April 07, 2026
Robert Half provides staffing and consulting services to global clients across accounting, finance, IT, legal, and creative sectors.
Via
The Motley Fool
Topics
Regulatory Compliance
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
April 03, 2026
As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...
Via
MarketMinute
Topics
Intellectual Property
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation
April 03, 2026
By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...
Via
Finterra
Topics
Economy
Intellectual Property
World Trade
2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory
↗
April 02, 2026
Dividend payers might become more popular if the recent volatility continues. These two stocks are great picks to weather the storm.
Via
The Motley Fool
Topics
Economy
Retirement
Stocks
Roivant and Immunovant Solidify Market Leadership as Brepocitinib and FcRn Programs Hit Critical Clinical Milestones
April 02, 2026
The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that...
Via
MarketMinute
Topics
Intellectual Property
Dow, S&P 500, Nasdaq: From Morning Meltdown to Midday "Meh"
↗
April 02, 2026
Markets opened lower on Iran fears and a Tesla stumble, but bounced back. Here's what investors need to know about Thursday's volatile session.
Via
The Motley Fool
Topics
Government
Stocks
World Trade
< Previous
1
2
3
4
5
6
7
8
9
...
72
73
Next >
